Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Authors not listed

NGM Biopharmaceuticals, Inc · 2020

Abstract

This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2020). A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). <em>NGM Biopharmaceuticals, Inc</em>. https://clinicaltrials.gov/study/NCT04465955
Vancouver
Anonymous. A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). NGM Biopharmaceuticals, Inc. 2020.
BibTeX
@misc{anon2020APhase, title = {A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)}, author = {Anonymous}, journal = {NGM Biopharmaceuticals, Inc}, year = {2020}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings